

Ulrich Brinkmann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5056583/ulrich-brinkmann-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	9,844 citations	47 h-index	98 g-index
150 ext. papers	10,596 ext. citations	7.4 avg, IF	6.05 L-index

#	Paper	IF	Citations
144	Circular RNAs With Efficacy in Preclinical and Models of Esophageal Squamous Cell Carcinoma.. <i>Cancer Genomics and Proteomics</i> , 2022 , 19, 283-298	3.3	1
143	Bispecific antibodies. <i>Science</i> , 2021 , 372, 916-917	33.3	15
142	Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy. <i>Anticancer Research</i> , 2021 , 41, 4185-4202	2.3	0
141	Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical Models. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 497-514	3.3	0
140	The Contorsbody, an antibody format for agonism: Design, structure, and function. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 1210-1220	6.8	1
139	Diphthamide-deficiency syndrome: a novel human developmental disorder and ribosomopathy. <i>European Journal of Human Genetics</i> , 2020 , 28, 1497-1508	5.3	2
138	Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 1221-1227	6.8	13
137	MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 1-23	3.3	17
136	Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. <i>Nature Communications</i> , 2020 , 11, 4974	17.4	9
135	Micro RNAs Promoting Growth and Metastasis in Preclinical Models of Subcutaneous Melanoma. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 651-667	3.3	1
134	microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical Models. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 453-468	3.3	1
133	DPH1 syndrome: two novel variants and structural and functional analyses of seven missense variants identified in syndromic patients. <i>European Journal of Human Genetics</i> , 2020 , 28, 64-75	5.3	5
132	Back-to-Germline (B2G) Procedure for Antibody Devolution. <i>Antibodies</i> , 2019 , 8,	7	2
131	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. <i>MAbs</i> , 2019 , 11, 1402-1414	6.6	6
130	Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids. <i>Nucleic Acids Research</i> , 2019 , 47, e55	20.1	5
129	Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2. <i>Biological Chemistry</i> , 2019 , 400, 501-512	4.5	1
128	The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 1-19	3.3	20

127	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019 , 154, 21-31	4.6	51
126	Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression. <i>Nucleic Acids Research</i> , 2019 , 47, 953-969	20.1	21
125	Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. <i>Biological Chemistry</i> , 2019 , 400, 343-350	4.5	7
124	Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress. <i>Redox Biology</i> , 2019 , 20, 146-156	11.3	11
123	Effects of Ultrasonic Dispersion Energy on the Preparation of Amorphous SiO ₂ Nanomaterials for In Vitro Toxicity Testing. <i>Nanomaterials</i> , 2018 , 9,	5.4	15
122	Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model. <i>Biological Chemistry</i> , 2018 , 399, 711-721	4.5	3
121	The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 17-39	3.3	32
120	Importance of diphthamide modified EF2 for translational accuracy and competitive cell growth in yeast. <i>PLoS ONE</i> , 2018 , 13, e0205870	3.7	6
119	The making of bispecific antibodies. <i>MAbs</i> , 2017 , 9, 182-212	6.6	442
118	Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing. <i>Scientific Reports</i> , 2017 , 7, 15480	4.9	6
117	Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins. <i>Toxins</i> , 2017 , 9,	4.9	5
116	Bispecific Antibodies 2017 , 75-97		
115	Hapten-Binding Bispecific Antibodies for the Targeted Delivery of siRNA and siRNA-Containing Nanoparticles. <i>Methods in Molecular Biology</i> , 2016 , 1364, 219-34	1.4	4
114	Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. <i>Molecular Oncology</i> , 2016 , 10, 1317-29	7.9	34
113	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. <i>MAbs</i> , 2016 , 8, 562-73	6.6	15
112	Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates. <i>Current Cancer Drug Targets</i> , 2016 , 16, 639-49	2.8	8
111	Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. <i>Immunological Reviews</i> , 2016 , 270, 165-77	11.3	9
110	Bispecific antibodies. <i>Drug Discovery Today</i> , 2015 , 20, 838-47	8.8	370

109	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 57-73	0.3	1
108	Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies. <i>FASEB Journal</i> , 2015 , 29, 1763-79	0.9	10
107	Loss of diphthamide pre-activates NF- κ B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 10732-7	11.5	27
106	TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 27497-50714	6.2	14
105	Induction of heat shock protein HSPA6 (HSP70B) upon HSP90 inhibition in cancer cell lines. <i>FEBS Letters</i> , 2015 , 589, 1450-8	3.8	15
104	A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. <i>Journal of Biological Chemistry</i> , 2014 , 289, 18693-706	5.4	43
103	Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 203601	3	89
102	Tumor-antigen-binding bispecific antibodies for cancer treatment. <i>Seminars in Oncology</i> , 2014 , 41, 653-69.5	6.5	62
101	Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2014 , 11, 25-38	3.3	45
100	PK modulation of haptenylated peptides via non-covalent antibody complexation. <i>Journal of Controlled Release</i> , 2013 , 171, 48-56	11.7	8
99	Quantification of cell surface proteins with bispecific antibodies. <i>Protein Engineering, Design and Selection</i> , 2013 , 26, 645-54	1.9	13
98	A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. <i>PLoS ONE</i> , 2013 , 8, e54923	3.7	57
97	The intriguing options of multispecific antibody formats for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2013 , 10, 1-18	3.3	18
96	The emerging role of new protein scaffold-based agents for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2013 , 10, 155-68	3.3	33
95	Human-protein-derived peptides for intracellular delivery of biomolecules. <i>Biochemical Journal</i> , 2012 , 442, 583-93	3.8	11
94	Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. <i>Archives of Biochemistry and Biophysics</i> , 2012 , 526, 206-18	4.1	39
93	Bispecific antibody derivatives based on full-length IgG formats. <i>Methods in Molecular Biology</i> , 2012 , 901, 247-63	1.4	15
92	Generation of fluorescent IgG fusion proteins in mammalian cells. <i>Methods in Molecular Biology</i> , 2012 , 901, 265-76	1.4	1

91	Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. <i>Protein Engineering, Design and Selection</i> , 2012 , 25, 571-80	1.9	20
90	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. <i>MAbs</i> , 2012 , 4, 653-63	6.6	130
89	Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2369-78	5.9	51
88	LIGHT (TNFSF14) inhibits adipose differentiation without affecting adipocyte metabolism. <i>International Journal of Obesity</i> , 2011 , 35, 208-16	5.5	19
87	Bispecific digoxigenin-binding antibodies for targeted payload delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 8194-9	11.5	51
86	Fluorescent Citrine-IgG fusion proteins produced in mammalian cells. <i>MAbs</i> , 2010 , 2, 648-61	6.6	11
85	Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 795-802	4.9	3
84	Disulfide-Stabilized Fv Fragments 2010 , 181-189		2
83	Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2. <i>Blood</i> , 2010 , 116, 4304-4304	2.2	
82	Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. <i>Endocrinology</i> , 2009 , 150, 5373-83	4.8	20
81	Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. <i>Frontiers in Bioscience - Landmark</i> , 2008 , 13, 7243-9	2.8	12
80	Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. <i>World Journal of Gastroenterology</i> , 2008 , 14, 2810-7	5.6	3
79	Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 77-83	1.9	10
78	Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 4240-5	11.5	87
77	High throughput functional genomics: identification of novel genes with tumor suppressor phenotypes. <i>International Journal of Cancer</i> , 2005 , 113, 434-9	7.5	15
76	Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes. <i>Bioinformatics</i> , 2005 , 21, 2766-72	7.2	3
75	High-throughput functional genomics identifies genes that ameliorate toxicity due to oxidative stress in neuronal HT-22 cells: GFPT2 protects cells against peroxide. <i>Molecular and Cellular Proteomics</i> , 2004 , 3, 834-40	7.6	27
74	Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. <i>Clinical Chemistry</i> , 2004 , 50, 448-51	5.5	7

73	Development of secreted proteins as biotherapeutic agents. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 551-8	5.4	57
72	Sequence diversity and functional characterization of the 5' regulatory region of human CYP2C19. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 199-206		13
71	Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 51-60	6.1	65
70	CSE1L/CAS: its role in proliferation and apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2003 , 8, 39-44	5.4	81
69	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2003 , 58, 809-12	2.8	124
68	Functional characterization of the 5'-regulatory region of human CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P60-P60	6.1	
67	Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. <i>New England Journal of Medicine</i> , 2003 , 348, 1442-8	59.2	611
66	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. <i>Gastroenterology</i> , 2003 , 124, 26-33	13.3	266
65	Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. <i>American Journal of Pathology</i> , 2003 , 163, 1567-77	5.8	81
64	Medikamente nach Maß. <i>Pharmakogenetik. Biologie in Unserer Zeit</i> , 2002 , 32, 344-350	0.1	1
63	MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 526-34	3.8	201
62	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 584-94	6.1	243
61	Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 1847-54	12.7	215
60	Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 591-5		175
59	Influence of GSTT1 and GSTM1 genotypes on sunburn sensitivity. <i>Molecular Diagnosis and Therapy</i> , 2002 , 2, 147-54		21
58	Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. <i>Biochemical Journal</i> , 2001 , 356, 867-73	3.8	20
57	Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. <i>Biochemical Journal</i> , 2001 , 356, 867-873	3.8	37
56	Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits. <i>Pharmacogenomics</i> , 2001 , 2, 303-5	2.6	

55	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 169-74	6.1	54 ¹
54	ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. <i>Pharmacogenomics</i> , 2001 , 2, 51-64	2.6	168
53	Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. <i>Drug Discovery Today</i> , 2001 , 6, 835-839	8.8	75
52	High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. <i>International Journal of Molecular Medicine</i> , 2001 , 7, 489-94	4.4	37
51	Recombinant immunotoxins for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2001 , 1, 693-702	5.4	9
50	Cse1l is essential for early embryonic growth and development. <i>Molecular and Cellular Biology</i> , 2001 , 21, 7020-4	4.8	28
49	Frequency of C3435T polymorphism of MDR1 gene in African people. <i>Lancet, The</i> , 2001 , 358, 383-4	4.0	237
48	Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 111-21		188
47	Stabilization Strategies and Application of Recombinant Fvs and Fv Fusion Proteins 2001 , 593-615		
46	Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 557-65		146
45	Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. <i>Cancer Gene Therapy</i> , 2000 , 7, 91-6	5.4	20
44	How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 869-76	5.9	27
43	Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 3473-8	11.5	1017
42	High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 9287-92	11.5	58
41	Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. <i>Human Gene Therapy</i> , 1999 , 10, 923-34	4.8	18
40	Tissue-specific alternative splicing of the CSE1L/CAS (cellular apoptosis susceptibility) gene. <i>Genomics</i> , 1999 , 58, 41-9	4.3	12
39	Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. <i>American Journal of Dermatopathology</i> , 1999 , 21, 125-8	0.9	35
38	CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. <i>American Journal of Human Genetics</i> , 1998 , 62, 509-13	11	49

37	Role of caspases in immunotoxin-induced apoptosis of cancer cells. <i>Biochemistry</i> , 1998 , 37, 16934-42	3.2	79
36	The hCSE1/CAS protein is phosphorylated by HeLa extracts and MEK-1: MEK-1 phosphorylation may modulate the intracellular localization of CAS. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 250, 623-8	3.4	16
35	A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. <i>Journal of Molecular Biology</i> , 1998 , 281, 475-83	6.5	33
34	Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 300-4	11.5	120
33	PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 10757-62	11.5	66
32	Antisense inhibition of CAS, the human homologue of the yeast chromosome segregation gene CSE1, interferes with mitosis in HeLa cells. <i>Biochemistry</i> , 1997 , 36, 9493-500	3.2	27
31	Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation. <i>Journal of Molecular Biology</i> , 1997 , 268, 107-17	6.5	28
30	Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1997 , 2, 192-8	5.4	20
29	Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. <i>International Journal of Cancer</i> , 1997 , 71, 638-44	7.5	14
28	Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. <i>Biochemistry</i> , 1996 , 35, 6891-9	3.2	78
27	The human CAS protein which is homologous to the CSE1 yeast chromosome segregation gene product is associated with microtubules and mitotic spindle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 2670-4	11.5	51
26	Recombinant immunotoxins: protein engineering for cancer therapy. <i>Trends in Molecular Medicine</i> , 1996 , 2, 439-46		16
25	Recombinant immunotoxins. <i>Breast Cancer Research and Treatment</i> , 1996 , 38, 3-9	4.4	18
24	Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. <i>Nature Biotechnology</i> , 1996 , 14, 1239-45	44.5	127
23	The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. <i>Genome Research</i> , 1996 , 6, 187-94	9.7	77
22	Expression Cloning of cDNAs That Render Cancer Cells Resistant to Pseudomonas and Diphtheria Toxin and Immunotoxins. <i>Molecular Medicine</i> , 1995 , 1, 206-216	6.2	40
21	Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. <i>Protein Engineering, Design and Selection</i> , 1995 , 8, 1323-31	1.9	46
20	Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure. <i>Immunity</i> , 1995 , 2, 281-7	32.3	15

19	Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. <i>Molecular Immunology</i> , 1995 , 32, 249-58	4.3	43
18	Recombinant Immunotoxins: From Basic Research to Cancer Therapy. <i>Methods</i> , 1995 , 8, 143-156	4.6	18
17	Phage display of disulfide-stabilized Fv fragments. <i>Journal of Immunological Methods</i> , 1995 , 182, 41-50	2.5	30
16	Recombinant toxins: new therapeutic agents for cancer. <i>Annals of the New York Academy of Sciences</i> , 1995 , 758, 345-54	6.5	39
15	Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 10427-31	11.5	159
14	Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. <i>Protein Engineering, Design and Selection</i> , 1994 , 7, 697-704	1.9	81
13	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994 , 58, 142-9	7.5	42
12	Immunotoxins against cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1994 , 1198, 27-45	11.2	32
11	Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. <i>Biochemistry</i> , 1994 , 33, 5451-9	3.2	118
10	Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. <i>Bioconjugate Chemistry</i> , 1994 , 5, 321-6	6.3	9
9	Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. <i>Gene</i> , 1993 , 128, 43-9	3.8	154
8	A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 547-51	11.5	28
7	A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 7538-42	11.5	198
6	Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 3065-9	11.5	18
5	Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 3075-9	11.5	80
4	Renaturation of a single-chain immunotoxin facilitated by chaperones and protein disulfide isomerase. <i>Nature Biotechnology</i> , 1992 , 10, 682-5	44.5	51
3	A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. <i>Analytical Biochemistry</i> , 1992 , 205, 263-70 ^{3.1}		33 ²
2	B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 8616-20	11.5	210

- ¹ High-level expression of recombinant genes in *Escherichia coli* is dependent on the availability of the dnaY gene product. *Gene*, **1989**, 85, 109-14 3.8 34¹